Search

Your search keyword '"Cobimetinib"' showing total 143 results
Start Over Descriptor "Cobimetinib" Database Gale General OneFile
143 results on '"Cobimetinib"'

1. Research Data from Sheba Medical Center Update Understanding of Breast Cancer (Class Effect Unveiled: PPARg Agonists and MEK Inhibitors in Cancer Cell Differentiation)

Subjects
Drug therapy, Development and progression, Medical centers, Cell differentiation, Cobimetinib, Cancer research, Drug resistance -- Drug therapy -- Development and progression, Breast cancer -- Development and progression -- Drug therapy, Oncology, Experimental, Cancer -- Research
Abstract

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on breast cancer are discussed in a new report. According to news [...]

Published
2024

2. Revolution Medicines reports progress, expansion of combo strategy with RMC-4630

Subjects
AstraZeneca PLC, Drugs, Cobimetinib, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Revolution Medicines (RVMD) reported interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib in an oral presentation at the EORTC-NCI-AACR 32nd Symposium [...]

Published
2020

4. Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630

Subjects
Clinical trials, Vemurafenib, Cobimetinib, Business, News, opinion and commentary
Abstract

Revolution Medicines announced that interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib will be reported in an oral presentation in a [...]

Published
2020

6. Reports Summarize Non-Langerhans-Cell Histiocytosis Study Results from Giuseppe Giuffre and Co-Researchers (Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib)

Subjects
Lymphatic diseases -- Development and progression, Physical fitness, Langerhans-cell histiocytosis -- Development and progression, Cobimetinib, Biochemistry, Health
Abstract

2020 SEP 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Lymphatic Diseases and Conditions - Non-Langerhans-Cell Histiocytosis. [...]

Published
2020

7. Roche gets US FDA nod for Tecentriq plus Cotellic & Zelboraf to treat BRAF V600 mutation-positive advanced melanoma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Gene mutation -- Genetic aspects, Biotechnology industries -- Genetic aspects, Melanoma -- Genetic aspects -- Drug therapy, Drug approval, Pharmaceuticals and cosmetics industries, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

Roche announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The [...]

Published
2020

8. Revolution Medicines begins patient dosing in phase1 trial of RMC-4630 in combo with pembrolizumab to treat solid tumors

Subjects
Sanofi S.A. -- Product development, Drugs -- Product development, Cobimetinib, Tumors, Colorectal cancer, Pembrolizumab, Pharmaceutical industry -- Product development, Cancer patients, Non-small cell lung cancer, Pharmaceuticals and cosmetics industries
Abstract

Revolution Medicines, a clinical-stage oncology company, announced dosing of the first patient in a multicenter phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the companyÇÖs investigational SHP2 inhibitor, [...]

Published
2020

9. Findings from University Hospitals Leuven Broaden Understanding of Adenocarcinoma (Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review)

Subjects
Vemurafenib, Adenocarcinoma -- Genetic aspects, Physical fitness, Cobimetinib, Pancreatic cancer -- Genetic aspects, Gene mutation -- Genetic aspects, Journalistic ethics, Health
Abstract

2020 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Adenocarcinoma. According to news reporting [...]

Published
2020

10. DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity

Subjects
Physical fitness, Cancer -- Genetic aspects, Cobimetinib, Genes -- Genetic aspects, Skin cancer -- Genetic aspects, Gene mutation -- Genetic aspects, DNA -- Genetic aspects, Melanoma -- Genetic aspects, Antineoplastic agents, DNA repair -- Genetic aspects, Anopheles, Trametinib, Vemurafenib, Dabrafenib, Obesity, Technology, Skin, Editors, Health
Abstract

2020 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2020

11. Revolution Medicines' clinical-stage SHP2 inhibitor ProgramMulti-cohort phase 1/2 clinical programme of RMC-4630 gets US

Subjects
Cellular proteins -- Intellectual property, Drugs -- Intellectual property, Cobimetinib, Tyrosine, Cancer treatment, Trademarks, Phenols (Class of compounds), Pharmaceuticals and cosmetics industries
Abstract

Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, announced that the United States Patent and Trademark Office has issued US Patent No. [...]

Published
2020

12. Revolution Medicines announces trial exploring RMC-4630 w/ ERK inhibitor

Subjects
Pancreatic cancer, Drugs, Cobimetinib, Cancer treatment, Cancer, Clinical trials, Tumors, Business, News, opinion and commentary
Abstract

Revolution Medicines announced its intention to support the Netherlands Cancer Institute on a combination clinical study targeting two key nodes in the oncogenic RAS signaling pathway and to supply its [...]

Published
2020

13. Revolution Medicines begins phase 1b/2 study of RMC-4630-02 in combo with cobimetinib in patients with relapsed/refracto

Subjects
Vemurafenib, Cobimetinib, Drugs, Tumors, Pharmaceuticals and cosmetics industries, Cotellic (Medication) -- Product development
Abstract

Revolution Medicines, a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, announced dosing of the first patient in an open-label, [...]

Published
2019

14. Data on Solid Cancer Described by Researchers at Dana-Farber Cancer Institute [Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors]

Subjects
Physical fitness, Cancer -- Care and treatment, Cobimetinib, Cancer research, Obesity, Medical research, Tumors, Editors, Health
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Solid Cancer is now available. According [...]

Published
2019

15. Data from Flinders University Advance Knowledge in Melanoma (Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma)

Subjects
Cobimetinib, Medical research, Melanoma -- Care and treatment, Antineoplastic agents, Obesity, Vemurafenib, Clinical trials, Cancer metastasis, Editors, Health
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Melanoma. According to news reporting [...]

Published
2019

16. Patent Application Titled 'Deuterated Venetoclax' Published Online (USPTO 20190225607)

Subjects
Physical fitness, Cobimetinib, Patient compliance, Obinutuzumab, Antiarrhythmia agents -- Intellectual property, Antineoplastic agents -- Intellectual property, Decitabine, Obesity, Bendamustine, Editors, Health
Abstract

2019 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2019

17. Drug & Device Pipeline News

Subjects
Vemurafenib, Atezolizumab, Cobimetinib, Nivolumab, Cannabidiol, Health
Abstract

Drug & Device Pipeline News Company Drug/Device Medical Condition COVID-19 Trials and Actions BioAegis recombinant human hospitalized Therapeutics plasma gelsolin patients with severe (rhu-pGSN) COVID-19 pneumonia Eli Lilly LY-CoV555 prevention [...]

Published
2020

18. Supply Of The Drug 'cobimetinib' For Citizens Of The Russian Federation Who Have The Right To Free Provision Of Drugs And Medical Products In Accordance With The Decree Of The Government Of The Russia

Subjects
Medical supplies, Drugs, Cobimetinib, Health care reform, Business, international
Abstract

Tenders are invited for Supply of the drug 'cobimetinib' for citizens of the russian federation who have the right to free provision of drugs and medical products in accordance with [...]

Published
2020

19. Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

Subjects
Vemurafenib, Atezolizumab, Cobimetinib, Cancer research, Immunotherapy, Adjuvant chemotherapy, Business, international, Law, Tecentriq (Medication)
Abstract

(GlobeNewswire) - People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with [...]

Published
2020

20. Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

Subjects
Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Cancer research, Biotechnology industries, Immunotherapy, Adjuvant chemotherapy, Business, international, Tecentriq (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) [...]

Published
2020

21. Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Exelixis Inc. -- Product development, Cabozantinib, Cobimetinib, Chemotherapy, Biotechnology industries -- Product development, Tumors, Business, Business, international
Abstract

- Phase 1 clinical trial expected to begin in Q1 2021 - - Under the terms of the companies' agreement, Exelixis will make an option exercise payment of $12 million [...]

Published
2020

22. Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

Subjects
United States. Food and Drug Administration, Exelixis Inc. -- Product development, Cabozantinib, Cobimetinib, Biotechnology industries -- Product development, Biopharmaceuticals -- Product development, Antibodies, Business, Business, international
Abstract

- Phase 1 clinical trial planned for early 2021, pending the FDA's acceptance of Exelixis' planned IND filing - - Under the terms of the companies' agreement, Exelixis has made [...]

Published
2020

23. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December

Subjects
Exelixis Inc., Cabozantinib, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at [...]

Published
2020

24. Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b|2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

Subjects
Clinical trials, Vemurafenib, Cobimetinib, Tumors, Business, international, Law
Abstract

(GlobeNewswire) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the companys [...]

Published
2020

25. Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

Subjects
Clinical trials, Vemurafenib, Cobimetinib, Tumors, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Oct 12, 2020 (GLOBE NEWSWIRE via COMTEX) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted [...]

Published
2020

26. Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

Subjects
Exelixis Inc., Cabozantinib, Atezolizumab, Cobimetinib, Tyrosine, Biotechnology industries, Vascular endothelial growth factor, Phenols (Class of compounds), Business, Business, international
Abstract

- In preclinical studies, XL092 demonstrated robust target and tumor growth inhibition - - Clinical pharmacokinetic (PK) data suggest a significantly shorter half-life than cabozantinib - - Phase 1 evaluation [...]

Published
2020

27. Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

Subjects
Roche Holding AG, Palbociclib, Thyroid cancer, Atezolizumab, Cobimetinib, Bevacizumab, Biotechnology industries, Prostate cancer, Obinutuzumab, COVID-19, Antineoplastic agents, Alectinib, Business, international, Rozlytrek (Medication), Tecentriq (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers - New integrated analyses [...]

Published
2020

28. Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

Subjects
Exelixis Inc. -- Licensing agreements -- Product development, Cabozantinib, Cobimetinib, Tumors -- Drug therapy, Biological products -- Product development -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

- ICON-2 is pharmacologically more potent in vivo and in vitro, with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data presented [...]

Published
2020

29. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Subjects
Morgan Stanley, Exelixis Inc., Cabozantinib, Securities industry, Cobimetinib, Biotechnology industries, Securities industry, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at [...]

Published
2020

30. Joining a Hairy Cell Leukemia Clinical Trial

Subjects
Clinical trials, Cobimetinib, Obinutuzumab, Antineoplastic agents -- Product development, Hairy cell leukemia, Business, international, Law
Abstract

Kristie L. Kahl: Why is it important for patients to consider joining a clinical trial? Dr. Robert Kreitman: When you join a clinical trial, you're generally being treated by experts [...]

Published
2020

31. FDA APPROVALS ROUNDUP: MONJUVI, SPRAVATO, EPIDIOLEX

Subjects
United States. Food and Drug Administration, Vemurafenib, Atezolizumab, Cobimetinib, Respiratory system agents, Ustekinumab, Drug approval, Lymphomas -- Drug therapy, Biological products industry, Everolimus, Stem cell transplantation, News, opinion and commentary, Spravato (Medication), Epidiolex (Medication), Stelara (Medication)
Abstract

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: By Renee Matthews A weekly update on new drug approvals and indications from the US Food [...]

Published
2020

32. FDA APPROVES ATEZOLIZUMAB FOR BRAF V600 UNRESECTABLE OR METASTATIC MELANOMA

Subjects
United States. Food and Drug Administration, Vemurafenib, Atezolizumab, Cobimetinib, Melanoma, Drug approval, Cancer metastasis, News, opinion and commentary, Tecentriq (Medication)
Abstract

SILVER SPRING, MD -- The following information was released by the U.S. Food and Drug Administration (FDA): On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, [...]

Published
2020

33. FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma

Subjects
United States. Food and Drug Administration, Vemurafenib, Atezolizumab, Cobimetinib, Melanoma -- Drug therapy, Drug approval, Biological products industry, General interest, News, opinion and commentary, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

SOUTH SAN FRANCISCO: Genentech has issued the following news release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug [...]

Published
2020

34. FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Biotechnology industries, Drug approval, Melanoma -- Drug therapy, General interest, News, opinion and commentary, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

Basel: Roche Holding AG has issued the following press release: Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq(r) (atezolizumab) plus [...]

Published
2020

35. FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Gene mutation, Biotechnology industries, Melanoma -- Drug therapy, Drug approval, Business, Business, international, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

M2 PRESSWIRE-July 31, 2020-: FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma (C)1994-2020 M2 COMMUNICATIONS RDATE:31072020 Basel - Roche (SIX: RO, ROG; OTCQX: RHHBY) today [...]

Published
2020

36. FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Gene mutation, Biotechnology industries, Melanoma -- Drug therapy, Drug approval, Business, international, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq(R) (atezolizumab) plus [...]

Published
2020

37. Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma

Subjects
Exelixis Inc., Roche Holding AG, Clinical trials, Atezolizumab, Cobimetinib, Biotechnology industries, Renal cell carcinoma, Cancer metastasis, Antineoplastic agents, Business, Business, international, Cabometyx (Medication)
Abstract

- CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced [...]

Published
2020

38. Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Subjects
United States. Food and Drug Administration, Roche Holding AG, Precision medicine, Thyroid cancer, Atezolizumab, Drugs, Cobimetinib, Bevacizumab, Biotechnology industries, Obinutuzumab, Non-small cell lung cancer, Antineoplastic agents, Alectinib, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid [...]

Published
2020

39. Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Subjects
United States. Food and Drug Administration, Roche Holding AG, Precision medicine, Thyroid cancer, Atezolizumab, Drugs, Cobimetinib, Bevacizumab, Biotechnology industries, Obinutuzumab, Non-small cell lung cancer, Antineoplastic agents, Alectinib, Business, international, Law
Abstract

(GlobeNewswire) - Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid [...]

Published
2020

40. Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Subjects
United States. Food and Drug Administration, Roche Holding AG, Precision medicine, Thyroid cancer, Atezolizumab, Drugs, Cobimetinib, Bevacizumab, Obinutuzumab, Non-small cell lung cancer, Antineoplastic agents, Alectinib, Business, Business, international
Abstract

M2 PRESSWIRE-July 14, 2020-: Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers (C)1994-2020 M2 COMMUNICATIONS RDATE:14072020 - Roche will obtain co-development and co-commercialisation [...]

Published
2020

41. Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Subjects
United States. Food and Drug Administration, Roche Holding AG, Precision medicine, Thyroid cancer, Atezolizumab, Drugs, Cobimetinib, Bevacizumab, Obinutuzumab, Non-small cell lung cancer, Antineoplastic agents, Alectinib, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, [...]

Published
2020

42. Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Subjects
Takeda Pharmaceutical Company Ltd., Exelixis Inc., Roche Holding AG, Clinical trials, Atezolizumab, Cobimetinib, Biotechnology industries, Prostate cancer -- Care and treatment, Pharmaceutical industry, Cancer metastasis -- Care and treatment, Antineoplastic agents, Business, Business, international, Cabometyx (Medication)
Abstract

- Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial - - CONTACT-02 is the second of three phase 3 pivotal trials that are part of a [...]

Published
2020

43. Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

Subjects
Sanofi S.A., Clinical trials, Drugs, Cobimetinib, Medical research, Pembrolizumab, Pharmaceutical industry, Non-small cell lung cancer, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Jun 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today [...]

Published
2020

45. Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer

Subjects
Exelixis Inc., Roche Holding AG, Cabozantinib, Atezolizumab, Cobimetinib, Chemotherapy, Biotechnology industries, Small cell lung cancer, Sorafenib, Prostate cancer, Non-small cell lung cancer, Cancer metastasis, Cancer treatment, Lung cancer, Business, Business, international, Cabometyx (Medication)
Abstract

- Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial - - CONTACT-01 is the first of three phase 3 pivotal trials that are part of a [...]

Published
2020

46. Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

Subjects
Clinical trials, Drugs -- Product development, Cobimetinib, Medical research, Cancer treatment, Cancer, Tumors, Business, international, Law
Abstract

(GlobeNewswire) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a [...]

Published
2020

47. Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

Subjects
Clinical trials, Drugs -- Product development, Cobimetinib, Medical research, Cancer treatment, Cancer, Tumors, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Jun 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Study Evaluates Combination Treatment with Investigational SHP2 and KRAS Inhibitors in Patients with KRAS Mutant Solid Tumors Revolution Medicines, Inc. [...]

Published
2020

48. Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

Subjects
The Goldman Sachs Group Inc., Exelixis Inc., Financial markets, Cabozantinib, Investment banks, Cobimetinib, Biotechnology industries, Business, Business, international
Abstract

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. -- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will participate in fireside chats at the [...]

Published
2020

49. Delivery Of Medicinal Products - General And For The Treatment Of Oncological Diseases, Divided Into 2 Separate Items

Subjects
Durvalumab, Cobimetinib, Ribociclib, Avelumab, Trametinib, Mitomycin, Doxorubicin, Anthracyclines, Powders (Particulate matter), Diseases, Business, international
Abstract

Contract notice: Delivery of medicinal products - general and for the treatment of oncological diseases, Divided into 2 separate items 1.1 L01XE38 Cobimetinib oral form mg 56 700 414 038.52 [...]

Published
2020

50. Cobimetinib

Subjects
Vemurafenib, Cobimetinib, Contractors, Business, international
Abstract

Contract Awarded for Cobimetinib Title : Purchase of medicine cobetinib and vemurafenib Quantity: 63.00 COMPRIMIDO Unit Price without taxes: $ 1.904,7619 Contractor name : ROCHE INTERNATIONAL LTD (RUT 210101830017) Contractor [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results